Search Results - "KNOEBL, P."

Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial by Chowdary, P., Lethagen, S., Friedrich, U., Brand, B., Hay, C., Abdul Karim, F., Klamroth, R., Knoebl, P., Laffan, M., Mahlangu, J., Miesbach, W., Dalsgaard Nielsen, J., Martín‐Salces, M., Angchaisuksiri, P.

“…Summary Background Prophylaxis with either intravenous (i.v.) factor VIII (FVIII) or FIX is the gold standard of care for patients with severe hemophilia. A…”
Get full text

A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A by Eichler, H., Angchaisuksiri, P., Kavakli, K., Knoebl, P., Windyga, J., Jiménez‐Yuste, V., Hyseni, A., Friedrich, U., Chowdary, P.

“…Essentials explorer™3 was a double‐blinded, multiple‐dose escalation trial of subcutaneous concizumab. A pharmacodynamic relationship for unbound TFPI and…”
Get full text

Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) by KNOEBL, P., MARCO, P., BAUDO, F., COLLINS, P., HUTH‐KÜHNE, A., NEMES, L., PELLEGRINI, F., TENGBORN, L., LÉVESQUE, H.

“…Background:  Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies against coagulation factor VIII and characterized by spontaneous…”
Get full text

Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry by Tengborn, L, Baudo, F, Huth-Kühne, A, Knoebl, P, Lévesque, H, Marco, P, Pellegrini, F, Nemes, L, Collins, P

“…Please cite this paper as: Tengborn L, Baudo F, Huth‐Kühne A, Knoebl P, Lévesque H, Marco P, Pellegrini F, Nemes L, Collins P on behalf of the EACH2 registry…”
Get full text

Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma by GORCZYCA, M. E., NAIR, S. C., JILMA, B., PRIYA, S., MALE, C., REITTER, S., KNOEBL, P., GILBERT, J. C., SCHAUB, R. G., Dockal, M., McGINNESS, K. E., PABINGER, I., SRIVASTAVA, A.

“…Background:  Tissue factor pathway inhibitor (TFPI) is the major inhibitor of tissue factor‐initiated coagulation, making it an interesting and novel…”
Get full text

The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients by Perkhofer, S, Lass-Flörl, C, Hell, M, Russ, G, Krause, R, Hönigl, M, Geltner, C, Auberger, J, Gastl, G, Mitterbauer, M, Willinger, B, Knöbl, P, Resch, G, Waldner, R, Makrai, A, Hartmann, G, Girschikofsky, M, Greil, R

“…Abstract A prospective, observational, multicentre study was performed to assess the incidence, diagnosis, epidemiology and outcome of invasive mould…”
Get full text

TREATMENT BURDEN AND PATIENT PREFERENCE IN PATIENTS WITH HEMOPHILIA A OR B WITH INHIBITORS ON CONCIZUMAB PROPHYLAXIS: RESULTS FROM THE PHASE 3 EXPLORER7 STUDY by K Hampton, P Knoebl, J Odgaard-Jensen, O Stasyshyn, JJT Zaw, JS Neergaard, B Zulfikar, GG Fabbron

“…Introduction: Concizumab is a humanised, recombinant monoclonal antibody administered to patients with haemophilia A/B with inhibitors (HAwI/HBwI) as a…”
Get full text

PB2305: EFGARTIGIMOD: CLINICAL DEVELOPMENT OF A NOVEL FCRN ANTAGONIST IN THE TREATMENT OF AUTOIMMUNE DISEASES by Knoebl, P., Haard, H., Parys, W., Ulrichts, P., Rocca, F., Guglietta, A., Ayguasanosa, J.

Get full text

Postoperative paraneoplastic factor VIII auto-antibodies in patients with solid tumours by REITTER, S., KNOEBL, P., PABINGER, I., LECHNER, K.

“…Paraneoplastic FVIII antibodies may occur concurrent with the diagnosis or at various times after diagnosis and treatment of cancer. Between 2002 and 2009, we…”
Get full text

Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura by L. Kaynar, P. Coppo, M. Scully, J. De La Rubia, F. Peyvandi, S. Cataland, J. A. Kremer Hovinga, P. Knoebl, K. Pavenski, J. Minkue Mi Edou, F. Callewaert, R. De Passos Sousa

Get full text

Safety of caplacizumab in patients without documented severe adamts13 deficiency during the hercules study by S. Besisik, J. De La Rubia, F. Peyvandi, M. Scully, S. Cataland, P. Coppo, J. A. Kremer Hovinga, P. Knoebl, A. Metjian, K. Pavenski, H. De Winter, R. De Passos Sousa, F. Callewaert

Get full text

Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial by DUSCHEK, N., VAFAIE, M., SKRINJAR, E., HIRSCH, K., WALDHÖR, T., HÜBL, W., BERGMAYR, W., KNOEBL, P., ASSADIAN, A.

“…Background: Although unfractionated heparin (UFH) is an effective antithrombotic agent in endovascular interventions for the treatment of peripheral occlusive…”
Get full text

OUTCOMES OF PATIENTS WITH WORSENING ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) DESPITE DAILY THERAPEUTIC PLASMA EXCHANGE IN THE PHASE 3 HERCULES TRIAL by M. Scully, J.L. Rubia, F. Peyvandi, S. Cataland, P. Coppo, J.A.K. Hovinga, P. Knoebl, K. Pavenski, F. Callewaert, J.M.M. Edou, R.P. Sousa

Get full text

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura by Peyvandi, F., Scully, M., Kremer Hovinga, J. A., Knöbl, P., Cataland, S., De Beuf, K., Callewaert, F., De Winter, H., Zeldin, R. K.

“…Essentials Acquired thrombotic thrombocytopenic purpura (aTTP) is linked with significant morbidity/mortality. Caplacizumab's effect on major thromboembolic…”
Get full text

Post-transplant acute myeloid leukemia (PT-AML) by THALHAMMER-SCHERRER, R, WIESELTHALER, G, MUEHLBACHER, F, WOLNER, E, KLEPETKO, W, LECHNER, K, JAEGER, U, KNOEBL, P, SCHWARZINGER, I, SIMONITSCH, I, MITTERBAUER, G, BERLAKOVICH, G, MANNHALTER, C, HAAS, O, MAYER, G

“…Acute myeloid leukemia following organ transplantation (PT-AML) is a rare event with only a few published cases in the literature. We present three patients…”
Get full text

OC 14.5 Plasma Exchange-free Management of Immune Thrombotic Thrombocytopenic Purpura: The Austrian-German Experience by Kühne, L., Knoebl, P., Eller, K., Buxhofer-Ausch, V., Brinkkoetter, P., Völker, L.

Get full text

High proportion of patients with bleeding of unknown cause in persons with a mild‐to‐moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB) by Gebhart, J., Hofer, S., Panzer, S., Quehenberger, P., Sunder‐Plassmann, R., Hoermann, G., Eigenbauer, E., Haslacher, H., Kepa, S., Kyrle, P. A., Eichinger, S., Knöbl, P., Eischer, L., Mannhalter, C., Ay, C., Pabinger, I.

“…Introduction Data on clinical characteristics and the prevalence of underlying coagulopathies in patients with mild‐to‐moderate bleeding disorders (MBDs) are…”
Get full text

NET untangled in TMA? by Knobl, P

Get full text

Consensus statement for cancer patients requiring intensive care support by Kiehl, M. G., Beutel, G., Böll, B., Buchheidt, D., Forkert, R., Fuhrmann, V., Knöbl, P., Kochanek, M., Kroschinsky, F., La Rosée, P., Liebregts, T., Lück, C., Olgemoeller, U., Schalk, E., Shimabukuro-Vornhagen, A., Sperr, W. R., Staudinger, T., von Bergwelt Baildon, M., Wohlfarth, P., Zeremski, V., Schellongowski, P.

“…This consensus statement is directed to intensivists, hematologists, and oncologists caring for critically ill cancer patients and focuses on the management of…”
Get full text

Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH‐AH 01/2010 study by Werwitzke, S., Geisen, U., Nowak‐Göttl, U., Eichler, H., Stephan, B., Scholz, U., Holstein, K., Klamroth, R., Knöbl, P., Huth‐Kühne, A., Bomke, B., Tiede, A.

“…Essentials Factor VIII (FVIII) binding IgG detected by ELISA could be an alternative to the Bethesda assay. We studied the performance of anti‐FVIII IgG ELISA…”
Get full text